I’m particular encouraged by Peter’s comment.
”Executive Director, Dr Pete Smith commented: “These are highly positive outcomes in a heavily pre- treated patient population. We await with interest the release of the poster at ASH in December. To see such meaningful clinical responses in a group that would typically be receiving palliative care is striking. It is also encouraging that the safety profile was manageable, even for this advanced patient population.””
No eagerly await the professional social media, interview appearances to get the word out.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-17
-
- There are more pages in this discussion • 215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |